What is ATRA's health score?

Atara Biotherapeutics, Inc. (ATRA) has a TradeApes health score of 55 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ATRA's estimated fair value?

Based on our 5-year discounted cash flow model, Atara Biotherapeutics, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is ATRA undervalued or overvalued?

Our model currently rates ATRA as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ATRA... Refresh in a moment for the full analysis.

Atara Biotherapeutics, Inc. (ATRA)

Healthcare Inconclusive inconclusive mixed

$10.27

Updated: 2026-06-04

TradeApes Score

Financial Strength

50 Mixed

Operating Trend

60 Healthy

Relative Value

70 Healthy

Capital Allocation

20 Stressed

Risk

65 Healthy

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− Significant dilution — share count up more than 5% year over year

Unlock Full Report →

3 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.